What is INBX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.40B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for INBX?

P/E (TTM) is n/a and 52-week range is $28.16 to $155.29 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s INBX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for INBX?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-7.65B, EPS (TTM) near $-8.88 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Inhibrx Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in La Jolla, California, US, 14.7M shares outstanding, ISIN US45720N1037 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Inhibrx Biosciences Inc

$INBX

Health Care · Biotechnology

IR Run Scenarios

$95.01

+2.43%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. The company is headquartered in La Jolla, California and currently employs 109 full-time employees. The company went IPO on 2024-05-28. The firm utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Employees

110

Website

inhibrx.com/

IPO

2024-05-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)